Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s disease

Basit Öğe Kaydı
dc.contributor.authorDüzgün, Nurşen
dc.contributor.authorAyaşlıoğlu, Ergin
dc.contributor.authorTutkak, Hüseyin
dc.contributor.authorAydıntuğ, Olcay T.
dc.date.accessioned2020-06-25T17:40:54Z
dc.date.available2020-06-25T17:40:54Z
dc.date.issued2005
dc.departmentKırıkkale Üniversitesi
dc.description.abstractSerum levels of proinflammatory cytokines interleukin-1 beta (IL-1beta), tumor necrosis factor alpha, (TNF-alpha), and their inhibitors, IL-1 receptor antagonist (IL-1ra) and soluble TNF receptor 1 (sTNFR1), were determined by enzyme-linked immunosorbent assay in 104 patients with Behcet's disease (65 active, 39 inactive) and 40 healthy controls. The levels of IL-1beta and IL-1ra were significantly higher in both active and inactive patients than in control subjects (P < 0.01 and P < 0.01, respectively). The concentrations of TNF-alpha and sTNFR1 were found to be higher in active patients than in controls (P < 0.01 and P < 0.001, respectively). There were no significant differences in the serum levels of these cytokines and their inhibitors between active and inactive patients. Significant increases in mean C-reactive protein level and erythrocyte sedimentation rate were found in patients with active vs inactive disease (P < 0.001 and P < 0.05, respectively). C-reactive protein values correlated with erythrocyte sedimentation rate but not with cytokines or their inhibitors. Our conclusion is that elevated serum TNF-alpha and sTNFR1 seem to be important inflammatory mediators in Behcet's disease. The statistically significant increase in these levels may arise from the severity of inflammation in the tissue or organ involved.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s00296-003-0400-6
dc.identifier.endpage5en_US
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue1en_US
dc.identifier.pmid14600787
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-003-0400-6
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3582
dc.identifier.volume25en_US
dc.identifier.wosWOS:000226665600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet's diseaseen_US
dc.subjectinterleukin-1en_US
dc.subjectinterleukin-1 receptor antagonisten_US
dc.subjectsoluble tumoren_US
dc.subjectnecrosis factor receptor 1en_US
dc.subjecttumor necrosis factoren_US
dc.titleCytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s diseaseen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Cytokine inhibitors soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's disease.pdf
Boyut:
195.09 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu